The Uttar Pradesh Pharmaceutical and Medical Device Industry Policy, 2023 became effective on June 8, 2023, covering a comprehensive range of healthcare manufacturing sectors. According to the policy document from the Food Safety and Drug Administration Department, the initiative encompasses pharmaceutical products, bulk drugs, active pharmaceutical ingredients, key starting materials, drug intermediates, medical devices, and related manufacturing infrastructure. The policy is administered by the Food Safety and Drug Administration Department with Invest UP serving as the principal facilitation agency.
The policy offers capital subsidy equal to 15% of eligible investment, capped at ₹200 crore for qualifying projects. As reported by Invest UP, additional support includes interest subsidy on plant and machinery, stamp-duty exemption, electricity-duty relief, research assistance, certification reimbursement, clinical-trial support, waste-management assistance, and logistics incentives. Eligible expenditures cover land, buildings, plant and machinery, laboratory equipment, utilities, research equipment, second-hand machinery, taxes and duties, and expenditure incurred before the eligible date.
According to Invest UP updates, the policy has resulted in tangible developments including a bulk-drug and pharmaceutical park in Lalitpur and a medical-device park covering about 350 acres in Sector 28 of the Yamuna Expressway Industrial Development Authority region. The policy framework covers pharmaceutical formulations, bulk drugs and active pharmaceutical ingredients, key starting materials and drug intermediates, medical devices and diagnostic equipment, research and development facilities, quality-testing and certification infrastructure, clinical research and product-validation activities, and common effluent-treatment and waste-management systems.
Eligible beneficiaries include pharmaceutical manufacturing units, medical-device manufacturing units, manufacturers of key starting materials, drug-intermediate manufacturers, active pharmaceutical ingredient and bulk-drug units, eligible greenfield projects, qualifying expansion or diversification projects, developers of pharmaceutical or medical-device parks, and research, testing and clinical-development facilities. The policy provides reimbursement of 75% of the cost of specified International Organization for Standardization certification and reimbursement of 50% of costs associated with other eligible certifications and quality approvals. As reported by Invest UP, applicants must prepare detailed project reports, secure land or apply for land in approved industrial areas, submit investment proposals through prescribed state mechanisms, and complete eligible investment within approved periods.
